Pyxis Oncology, Inc. announced its financial results for the third quarter of 2024. The company also provided updates on its clinical pipeline, highlighting upcoming data presentations for its lead drug candidates.
Preliminary data from the Phase 1 dose escalation trial of PYX-201 is scheduled to be announced at an investor event on Wednesday, November 20, 2024. Additionally, preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by the end of 2024.
The company reported an expected cash runway that will fund its operations into the second half of 2026. This financial outlook provides a clear timeline for the advancement of its clinical programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.